---
layout: post
title: "Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability"
date: 2026-02-05 18:35:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-04845
original_published: 2023-03-09 00:00:00 +0000
significance: 8.00
---

# Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 09, 2023 00:00 UTC
**Document Number:** 2023-04845

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Babson Diagnostics, Inc., for the Babson Diagnostics aC19G1, and Twist Bioscience Corporation for the SARS-CoV-2 NGS Assay. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by each Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/09/2023-04845/revocation-of-two-authorizations-of-emergency-use-of-in-vitro-diagnostic-devices-for-detection-andor)
- API: https://www.federalregister.gov/api/v1/documents/2023-04845

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
